Impact of antibacterials on subsequent resistance and clinical outcomes in adult patients with viral pneumonia: An opportunity for stewardship

Critical Care

Volumn 19, Issue 1, 2015, Pages

  Crotty, Matthew P ^a   Meyers, Shelby ^b   Hampton, Nicholas ^c   Bledsoe, Stephanie ^d   Ritchie, David J ^a,b   Buller, Richard S ^d   Storch, Gregory A ^d   Kollef, Marin H ^d   Micek, Scott T ^b  

^a BARNES JEWISH HOSPITAL   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

^c Center for Clinical Excellence   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFEPIME; LINEZOLID; MEROPENEM; VANCOMYCIN;

ADENOVIRIDAE; ADULT; AFRICAN AMERICAN; ARTICLE; BACTERIAL COLONIZATION; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; CORONAVIRIDAE; CORYNEBACTERIUM; ENTEROVIRUS; FEMALE; HUMAN; INFLUENZA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METAPNEUMOVIRUS; MORTALITY; PARAINFLUENZA VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATORY VIRUS; RETROSPECTIVE STUDY; RHINOVIRUS; SHORT COURSE THERAPY; VIRUS PNEUMONIA; AGED; COINFECTION; COMPLICATION; DRUG EFFECTS; HOSPITAL MORTALITY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIDRUG RESISTANCE; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; TREATMENT OUTCOME; VIROLOGY;

AGED; ANTI-BACTERIAL AGENTS; COINFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HOSPITAL MORTALITY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84947235295     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-015-1120-5     Document Type: Article

References (41)

1. Estenssoro E, Ríos FG, Apezteguía C, Reina R, Neira J, Ceraso DH, et al. Pandemic 2009 influenza A in Argentina: a study of 337 patients on mechanical ventilation. Am J Respir Crit Care Med. 2010;182:41-8.
2. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198:962-70.
3. Farias JA, Fernández A, Monteverde E, Vidal N, Arias P, Montes MJ, et al. Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina. Intensive Care Med. 2010;36:1015-22.
4. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, et al. Critically ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA. 2009;302:1872-9.
5. Martín-Loeches I, Sanchez-Corral A, Diaz E, Granada RM, Zaragoza R, Villavicencio C, et al. Community acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A (H1N1) virus. Chest. 2011;139:555-62.
6. Rice TW, Rubinson L, Uyeki TM, Vaughn FL, John BB, Miller 3rd RR, et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med. 2012;40:1487-98.
7. Webb SA, Pettilä V, Seppelt I, Bellomo R, Bailey M, Cooper DJ, et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med. 2009;361:1925-34.
8. Centers for Disease Control and Prevention (CDC). Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1)- United States, May-August 2009. Morb Mortal Wkly Rep. 2009;58:1071-4.
9. Gill JR, Sheng ZM, Ely SF, Guinee DG, Beasley MB, Suh J, et al. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med. 2010;134:235-43.
10. Mauad T, Hajjar LA, Callegari GD, da Silva LF, Schout D, Galas FR, et al. Lung pathology in fatal novel human influenza A (H1N1)infection. Am J Respir Crit Care Med. 2010;181:72-9.
11. Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004;113:701-7.
12. Berkley JA, Munywoki P, Ngama M, Kazungu S, Abwao J, Bett A, et al. Viral etiology of severe pneumonia among Kenyan infants and children. JAMA. 2010;303:2051-7.
13. Olsen SJ, Thamthitiwat S, Chantra S, Chittaganpitch M, Fry AM, Simmerman JM, et al. Incidence of respiratory pathogens in persons hospitalized with pneumonia in two provinces in Thailand. Epidemiol Infect. 2010;138:1811-22.
14. Hammitt LL, Kazungu S, Morpeth SC, Gibson DG, Mvera B, Brent AJ, et al. A preliminary study of pneumonia etiology among hospitalized children in Kenya. Clin Infect Dis. 2012;54:190-9.
15. Chen CJ, Lin PY, Tsai MH, Huang CG, Tsao KC, Wong KS, et al. Etiology of community-acquired pneumonia in hospitalized children in northern Taiwan. Pediatr Infect Dis J. 2012;31:196-201.
16. Techasaensiri B, Techasaensiri C, Mejías A, McCracken Jr GH, Ramilo O. Viral coinfections in children with invasive pneumococcal disease. Pediatr Infect Dis J. 2010;29:519-23.
17. Peltola V, Heikkinen T, Ruuskanen O, Jartti T, Hovi T, Kilpi T, et al. Temporal association between rhinovirus circulation in the community and invasive pneumococcal disease in children. Pediatr Infect Dis J. 2011;30:456-61.
18. Choi SH, Hong SB, Kim T, Kim SH, Huh JW, Do KH, et al. Clinical and molecular characterization of rhinoviruses A, B, and C in adult patients with pneumonia. J Clin Virol. 2015;63:70-5.
19. Kukavica-Ibrulj I, Hamelin ME, Prince GA, Gagnon C, Bergeron Y, Bergeron MG, et al. Infection with human metapneumovirus predisposes mice to severe pneumococcal pneumonia. J Virol. 2009;83:1341-9.
20. Michaels RH, Myerowitz RL. Viral enhancement of nasal colonization with Haemophilus influenzae type b in the infant rat. Pediatr Res. 1983;17:472-3.
21. Gross AE, Van Schooneveld TC, Olsen KM, Rupp ME, Bui TH, Forsung E, et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. Antimicrob Agents Chemother. 2014;58:5262-8.
22. Andruska A, Micek ST, Shindo Y, Hampton N, Colona B, McCormick S, et al. Pneumonia pathogen characterization is an independent determinant of hospital readmission. Chest. 2015;148:103-11.
23. Woo PC, Chiu SS, Seto WH, Peiris M. Cost-effectiveness of rapid diagnosis of viral respiratory tract infections in pediatric patients. J Clin Microbiol. 1997;35:1579-81.
24. Byington CL, Castillo H, Gerber K, Daly JA, Brimley LA, Adams S, et al. The effect of rapid respiratory viral diagnostic testing on antibiotic use in a children's hospital. Arch Pediatr Adolesc Med. 2002;156:1230-4.
25. Barenfanger J, Drake C, Leon N, Mueller T, Troutt T. Clinical and financial benefits of rapid detection of respiratory viruses: an outcomes study. J Clin Microbiol. 2000;38:2824-8.
26. Oosterheert JJ, van Loon AM, Schuurman R, Hoepelman AI, Hak E, Thijsen S, et al. Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection. Clin Infect Dis. 2005;41:1438-44.
27. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century: a clinical super-challenge. N Engl J Med. 2009;360:439-43.
28. Labelle AJ, Arnold H, Reichley RM, Micek ST, Kollef MH. A comparison of culture-positive and culture-negative health-care-associated pneumonia. Chest. 2010;137:1130-7.
29. Fariñas-Alvarez C, Fariñas MC, Fernández-Mazarrasa C, Llorca J, Delgado-Rodríguez M. Epidemiological differences between sepsis syndrome with bacteremia and culture-negative sepsis. Infect Control Hosp Epidemiol. 2000;21:639-44.
30. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-81.
31. Charlson M, Pompei P, Ales K, MacKenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83.
32. Polk RE, Fox C, Mahoney A, Letcavage J, MacDougall C. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis. 2007;44:664-70.
33. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:27-72.
34. Kollef MH, Micek ST. Strategies to prevent antimicrobial resistance in the intensive care unit. Crit Care Med. 2005;33:1845-53.
35. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:825-34.
36. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372:1539-48.
37. Shiley KT, Lautenbach E, Lee I. The use of antimicrobial agents after diagnosis of viral respiratory tract infections in hospitalized adults: antibiotics or anxiolytics. Infect Control Hosp Epidemiol. 2010;31:1177-83.
38. Fridkin SK, Edwards JR, Courval JM, Hill H, Tenover FC, Lawton R, et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med. 2001;135:175-83.
39. Dancer SJ. The problem with cephalosporins. J Antimicrob Chemother. 2001;48:463-78.
40. Tacconelli E, De Angelis G, Cataldo MA, Pozzi E, Cauda R. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother. 2008;61:26-38.
41. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med. 2000;342:710-21.